Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc Ltd. (Nasdaq: SPRC) has received approval from Soroka University Medical Center to conduct a clinical trial for its proprietary treatment SCI-210 in patients with autism spectrum disorder (ASD). The trial, approved by the Israeli Ministry of Health and the Ethics Committee, will evaluate the safety and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, in comparison to CBD monotherapy. This randomized, double-blind, placebo-controlled study will involve 60 children over 20 weeks, focusing on several key efficacy endpoints, including behavior assessments and therapeutic dosing.
SciSparc Ltd. (Nasdaq: SPRC) has announced promising results from pre-clinical studies on its collaboration with Clearmind Medicine Inc. regarding the drug candidate MEAI for cocaine addiction treatment. The studies indicate that MEAI may effectively reduce cravings without disrupting natural reward processes.
Conducted by Professor Gal Yadid at Bar Ilan University, the research suggests MEAI maintains natural rewards while addressing drug-seeking behavior. A provisional patent application for MEAI’s use in treating cocaine addiction was filed in June 2022, linking SciSparc's CannAmide™ with Clearmind’s MEAI.
SciSparc Ltd. (Nasdaq: SPRC) has received approvals from the Israeli Ministry of Health and the Ethics Committee of Soroka Medical Center to conduct a clinical trial for its proprietary treatment SCI-210 aimed at autism spectrum disorder (ASD). This study will compare SCI-210, a mix of cannabidiol and CannAmide™, against CBD monotherapy. The randomized, double-blind trial will involve 60 children over 20 weeks and focus on safety, tolerability, and efficacy using various measurement tools. The agreement with Soroka Medical Center highlights the company's commitment to advancing clinical programs alongside its other trials for Tourette syndrome and Alzheimer's disease.
SciSparc Ltd. (Nasdaq: SPRC) announced promising pre-clinical results in collaboration with Clearmind Medicine Inc. for treating obesity and metabolic disorders using a novel psychedelic molecule, MEAI. The study showed that MEAI led to a 20% weight loss in rodents while preserving lean mass. Additionally, this treatment improved insulin levels and glucose tolerance. SciSparc aims to penetrate the obesity treatment market projected to grow from $2.4 billion in 2022 to $54 billion by 2030. This collaboration highlights the potential for developing a significant drug candidate in an underserved market.
SciSparc Ltd. (Nasdaq: SPRC) announced a non-binding letter of intent to sell a 50% stake in its subsidiary, SciSparc Nutraceuticals Inc., which owns the WellutionTM brand, to Jeffs' Brands Ltd. for $3 million. The transaction is contingent on a definitive agreement. The company also plans to establish a joint venture with Jeffs' Brands for a new line of food supplements. WellutionTM is a leading seller on Amazon with over 40,000 product reviews, primarily rated highly.
SciSparc Ltd. (Nasdaq: SPRC) announced positive findings from its non-clinical study of SCI-210 for treating Status Epilepticus (SE) at Chaim Sheba Medical Center, Israel. The study revealed that SCI-210, combining Palmitoylethanolamide (PEA) and Cannabidiol (CBD), showed significantly improved neuronal protection and no mortality in tested models compared to control groups. The results suggest SCI-210 may be more effective than CBD alone, with lower concentration requirements. The press release emphasizes the potential benefits of SCI-210 for SE patients, highlighting a gap in effective treatments.
SciSparc Ltd. (Nasdaq: SPRC) announced on Nov. 29, 2022, that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share. This decision follows a period where the company's ordinary shares maintained a closing bid price of at least $1.00 for ten consecutive business days. With this compliance achieved, the previous bid price deficiency matter is now resolved.
On November 15, 2022, SciSparc Ltd. (Nasdaq: SPRC) announced its intention to form a joint venture with Jeffs' Brands Ltd. (Nasdaq: JFBR) to develop a new line of nutritional and dietary supplements. Both companies will hold a 50% stake in the joint venture, which is subject to definitive documentation. SciSparc will handle product development, leveraging Jeffs' Brands' e-commerce expertise for marketing. This collaboration aims to create products based on market demand analysis for high profitability, potentially enhancing both companies' market positions.
SciSparc Ltd. (Nasdaq: SPRC) has received a new patent (U.S. Patent No. 11,491,172) for compositions and methods enhancing antimicrobials. This marks the seventh patent granted in the U.S. and strengthens the company’s intellectual property portfolio, comprising nine patent families and two trademarks. SciSparc is a clinical-stage pharmaceutical firm focused on cannabinoid-based therapies, including treatments for Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder.
SciSparc Ltd. (Nasdaq: SPRC) announced positive interim results from its Phase IIa trial of SCI-110 for patients with Alzheimer’s Disease and agitation. The trial demonstrated that SCI-110 was safe at all tested doses, without serious adverse effects. Notably, 75% of participants did not require additional medications for agitation, and 75% experienced increased appetite. The open-label study included 20 patients, with interim results based on the first eight. SCI-110 aims to address the unmet need for safe treatment options in this patient population.